Jianfeng Group Subsidiary Receives Approval for Azilsartan Medoxomil Potassium API

Gelonghui May 8thZhejiang Jianfeng Group Co.,Ltd.(600668.SH) announced that its subsidiary, Anhui Biocompounds Pharmaceutical Co., Ltd. ("Biocompounds"), has received the "Approval Notice for Chemical Raw Material Drug Marketing Application" (Notice No.: 2026YS00399) from the National Medical Products Administration for the chemical raw material drug Miazatan Potassium. The receipt of this "Approval Notice for Chemical Raw Material Drug Marketing Application" by Anhui Biocompounds Pharmaceutical Co., Ltd. indicates that the raw material drug complies with the relevant technical standards for raw material drug evaluation in China and can be marketed in China, which will help expand the business scope of the subsidiary.

Azilsartan Medoxomil Potassium, developed by Takeda Pharmaceutical Company in Japan, is an oral prodrug that is rapidly hydrolyzed into the active ingredient azilsartan in the body. It exerts its antihypertensive effect by selectively blocking the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion. According to the CDE’s platform for registration information on raw materials and excipients, nine companies are listed with status “A” for Azilsartan Medoxomil Potassium, including Zhuhai Rundu Pharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.